A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

Cost Comparison Between Apixaban and Low Molecular Weight Heparin (LMWH) Among Venous Thromboembolism (VTE) Cancer Patients

The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.

Inclusion Criteria:

• Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021
• Evidence of active cancer
• At least 1 claim for apixaban or low molecular weight heparin (LMWH)
• Age 18 years or older

Exclusion Criteria:

• diagnosis of atrial fibrillation/flutter
• procedure for mechanical heart valve or inferior vena cava filter
• VTE diagnosis in the baseline period
• anticoagulant therapy in the baseline period
• pregnancy